{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:24:48Z","timestamp":1791829488848,"version":"4.3.4"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.08.003","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:34:26Z","timestamp":1760142866000},"page":"1685-1695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group"],"prefix":"10.1016","volume":"8","author":[{"given":"Roger","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Babjuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bukavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Bree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan Palou","family":"Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"McConkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Soloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Svatek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Shen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3546-9928","authenticated-orcid":false,"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.08.003_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"4 Pt 1","key":"10.1016\/j.euo.2025.08.003_b0020","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.juro.2007.05.148","article-title":"Management of low grade papillary bladder tumors","volume":"178","author":"Herr","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0025","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.7150\/jca.20003","article-title":"Papillary urothelial neoplasm of low malignant potential (PUNLMP) after initial TUR-BT: comparative analyses with noninvasive low-grade papillary urothelial carcinoma (LGPUC)","volume":"8","author":"Kim","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.euo.2025.08.003_b0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrurol.2010.208","article-title":"Contemporary management of low-risk bladder cancer","volume":"8","author":"Falke","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","article-title":"Prognostic value of the WHO1973 and WHO2004\/2016 classification systems for grade in primary Ta\/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel study","volume":"4","author":"van Rhijn","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0040","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0045","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International Bladder Cancer Group","volume":"5","author":"Tan","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0050","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.euo.2024.06.004","article-title":"Clinical validation of the intermediate-risk non\u2013muscle-invasive bladder cancer scoring system and substratification model proposed by the International Bladder Cancer Group: a multicenter Young Academic Urologists Urothelial Working Group Collaboration","volume":"7","author":"Soria","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","article-title":"Expectant management of small, recurrent, noninvasive papillary bladder tumors","volume":"170","author":"Soloway","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/00365590510031219","article-title":"T1 G1 urinary bladder carcinoma: fact or fiction?","volume":"39","author":"Mikulowski","year":"2005","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.euo.2025.08.003_b0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/JU.0000000000002678","article-title":"All high-grade Ta tumors should be classified as high risk: bacillus Calmette-Gu\u00e9rin response in high-grade Ta tumors","volume":"208","author":"Bree","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0070","unstructured":"WHO Classification of Tumours Editorial Board. Urinary and male genital tumours: WHO classification of tumours. ed. 5. Vol. 8. Lyon Cedex, France: IARC Publications; 2022."},{"key":"10.1016\/j.euo.2025.08.003_b0075","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2015.09.007","article-title":"Significance of a minor high-grade component in a low-grade noninvasive papillary urothelial carcinoma of bladder","volume":"47","author":"Reis","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euo.2025.08.003_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bju.14417","article-title":"A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens","volume":"123","author":"Mari","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.08.003_b0085","doi-asserted-by":"crossref","first-page":"69.e11","DOI":"10.1016\/j.urolonc.2023.12.008","article-title":"Impact of variant histology on upstaging and survival in patients with nonmuscle invasive bladder cancer undergoing radical cystectomy","volume":"42","author":"McFadden","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0090","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.eururo.2018.09.020","article-title":"BOXIT\u2014a randomised phase III placebo-controlled trial evaluating the addition of celecoxib to standard treatment of transitional cell carcinoma of the bladder (CRUK\/07\/004)","volume":"75","author":"Kelly","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0095","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.juro.2016.03.151","article-title":"A 10-item checklist improves reporting of critical procedural elements during transurethral resection of bladder tumor","volume":"196","author":"Anderson","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0100","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2020.06.051","article-title":"Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: a multicentre real-world experience from Scotland's quality performance indicators programme","volume":"78","author":"Mariappan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0105","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.08.003_b0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"Sylvester","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.eururo.2017.06.038","article-title":"Value of an immediate intravesical instillation of mitomycin c in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients","volume":"73","author":"Bosschieter","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0120","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200092","article-title":"A randomized trial of PHOTOdynamic surgery in non-muscle-invasive bladder cancer","volume":"1","author":"Heer","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.euo.2025.08.003_b0125","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.urology.2004.09.050","article-title":"Impact of superficial bladder cancer and transurethral resection on general health-related quality of life: an SF-36 survey","volume":"65","author":"Yoshimura","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.08.003_b0130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2018.10.027","article-title":"The perioperative morbidity of transurethral resection of bladder tumor: implications for quality improvement","volume":"125","author":"Pereira","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.08.003_b0135","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","article-title":"Long-term follow-up and factors associated with active surveillance failure for patients with non-muscle-invasive bladder cancer: the Bladder Cancer Italian Active Surveillance (BIAS) experience","volume":"5","author":"Contieri","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00345-024-05417-z","article-title":"Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer","volume":"43","author":"Zaurito","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2022.12.003","article-title":"A systematic review and meta-analysis of chemoablation for non-muscle-invasive bladder cancer","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.08.003_b0150","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.euo.2018.08.032","article-title":"Chemoablation with intensive intravesical mitomycin c treatment: a new approach for non-muscle-invasive bladder cancer","volume":"2","author":"Racioppi","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/JU.0000000000004296","article-title":"Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION)","volume":"213","author":"Prasad","year":"2025","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0165","doi-asserted-by":"crossref","unstructured":"Vilaseca AJG, Raventos C, Shore ND, et al. Safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non-muscle-invasive bladder cancer with select FGFR alterations. Presented at AUA; May 1, 2024; San Antonio, TX, USA.","DOI":"10.1016\/S0302-2838(24)01169-2"},{"key":"10.1016\/j.euo.2025.08.003_b0170","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/JU.0000000000003645","article-title":"Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS)","volume":"210","author":"Prasad","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0175","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0180","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2025.08.003_b0185","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0190","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0195","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.eururo.2016.01.006","article-title":"Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Gu\u00e9rin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer","volume":"69","author":"Arends","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0200","doi-asserted-by":"crossref","first-page":"485.e1","DOI":"10.1016\/j.urolonc.2023.06.017","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0205","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2024.01.004","article-title":"The elusive horizon: biomarkers in urothelial carcinoma","volume":"85","author":"Linscott","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.08.003_b0215","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.euo.2018.08.013","article-title":"Using grade of recurrent tumor to guide further therapy while on bacillus Calmette-Guerin: low-grade recurrences are not benign","volume":"2","author":"Li","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0220","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41581-022-00585-w","article-title":"Patient-centred clinical trial design","volume":"18","author":"Tong","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.euo.2025.08.003_b0225","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41591-022-01781-8","article-title":"Patient reported outcome assessment must be inclusive and equitable","volume":"28","author":"Calvert","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.08.003_b0230","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","article-title":"Financial toxicity among patients with prostate, bladder, and kidney cancer: a systematic review and call to action","volume":"4","author":"Bhanvadia","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.08.003_b0240","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jgs.18676","article-title":"Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer","volume":"72","author":"Garg","year":"2024","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euo.2025.08.003_b0245","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.3390\/ijerph182211877","article-title":"Patient-reported questionnaires to identify adverse drug reactions: a systematic review","volume":"18","author":"Lim","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.euo.2025.08.003_b0250","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/bju.15038","article-title":"CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer","volume":"125","author":"Mostafid","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.08.003_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-230082","article-title":"Ensuring successful biomarker studies in bladder preservation clinical trials for non-muscle invasive bladder cancer","volume":"10","author":"McConkey","year":"2024","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.08.003_b0260","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR inhibition in urothelial carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125002238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:42:05Z","timestamp":1778143325000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125002238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125002238"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.08.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermediate-risk Non\u2013muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}